Potent Immunity Achieved by Targeted, Sequential Administration of Recombinant DNA Vectors and Anchor-Modified Epitope Peptides

Transcription

1 Potent Immunity Achieved by Targeted, Sequential Administration of Recombinant DA Vectors and Anchor-Modified Epitope Peptides Adrian Bot, M.D., Ph.D. MannKind Corporation

2 MannKind Corporation, Valencia CA Diabetes Late stage development ncology Early stage development 2005 MannKind Corporation. All rights reserved. o copying or distribution of

3 Plasmid Vectors: a Typical Case of Yin & Yang Features Co-expression of Tc and Th epitopes CpG motifs Epitope Cluster Region (Antigen Fragment) Reconfigured Panel of Epitopes 2: Melan A 2: minigene Coding sequence 3:BGH polyadenylation region 1:CMV Enhancer/promoter Response T1 immune profile Limited magnitude 7:uclear Import Sequence 6:ISS 5:PMB rign of Replication psem Priming Vector (Plasmid) 3315 bp 4:kanamycin resistance gene 2005 MannKind Corporation. All rights reserved. o copying or distribution of

4 Targeted Intra-Lymph ode Delivery Imaging the inguinal lymph node Imaging of draining lymph nodes subsequent to administration of radiolabeled tracer Insertion of a needle into a superficial L Intralymphatic Injection 70mBq 99mTc Labelled Human Immunoglobulin 2005 MannKind Corporation. All rights reserved. o copying or distribution of

5 Immune Reactivity to a Tumor Associated Antigen Correlates with the Clinical utlook 2w mg of psem plasmid / infusion Ratio of SD patients / total within group Time to progression versus immune reactivity analysis (baseline and/or post-treatment) Immune patients on-immune patients P= Time to progression (days) 2005 MannKind Corporation. All rights reserved. o copying or distribution of

6 Two Mutually Exclusive Possibilities TAA immunity is mechanistically relevant The The immunization methodology needs improvement TAA immunity is largely an epiphenomenon 2005 MannKind Corporation. All rights reserved. o copying or distribution of

7 ptimization of Active Immunotherapeutic Strategies in Development Preclinical R&D Proof of concept, Efficacy exploratory trials trials 2005 MannKind Corporation. All rights reserved. o copying or distribution of

8 Building on the Immune Response Initiated by Plasmid DA: Preclinical Data 2w DA only Peptide only DA priming, Peptide boost Pre final boost Post final boost Melan A tetramer percent naïve Controls =5 Plasmid alone =20 Peptide alone =20 Plasmid / Peptide = MannKind Corporation. All rights reserved. o copying or distribution of

9 Robust Expansion of T Cell Immunity against Self or on-self Epitopes by Targeted, Lymph ode Delivery of Peptide Analogues 2w Plasmid Peptide HHD1 transgenic mice Melan A SSX YES PRAME PSMA Tyrosinase aïve 0% aïve 0.2% aïve 0.1% aïve 0% aïve 0.1% aïve 0.1% Tetramer Immunized 50% Immunized 18% Immunized 10.5% Immunized 49% Immunized 8.9% Immunized 8% CD MannKind Corporation. All rights reserved. o copying or distribution of

10 A ovel Immunotherapeutic Approach: Features Multi-component Plasmids and peptide analogues Peptides Peptides are anchor-modified Multivalent Co-targets Cancer cells eovasculature Targeted Approach Lymph Lymph node delivery Theranostic strategy

11 Prospective Immunization Protocol Expression profiling MHC Antigens Treatment cycles Diagnosis Enrollment Time. Initiation Amplification Induction Phase Maintenance Phase 2005 MannKind Corporation. All rights reserved. o copying or distribution of

12 A Multivalent Immunotherapeutic Candidate for Melanoma Plasmids (expressed portion) Peptides Targets 27va H Melan A MKC1207-D1 melan-a (A27va) MKC1207-P1 377va Melan A Tyrosinase H S S MKC1207-P2 Tyrosinase (V377(va)) Tyrosinase 165V MKC1207-D2 H 158va Y-ES (L158(va), MKC1207-P3 C165V) S YES-1 YES-1 SSX2 H 42V SSX (A42V) MKC1207-P4 SSX2 Confidential

13 A Multivalent Immunotherapeutic Candidate for Melanoma 2w Plasmids Peptides HHD1 transgenic mice Melan A tetramer Tyrosinase tetramer SSX2 tetramer Y-ES tetramer % Tetramer+ CD8 T cells Pre boost Post boost Pre boost Post boost Pre boost Post boost 0 aïve controls (=5) Plasmid alone (=10) Plasmid / Peptide (=50) 2005 MannKind Corporation. All rights reserved. o copying or distribution of

14 A Multivalent Immunotherapeutic Candidate for varian Carcinoma Plasmids (expressed portion) Peptides Targets 297V PRAME PSMA MKC1106-D1 MKC1106-D2 H H H 426va S Y-ES (L158(va), C165V) MKC1106-P3 MKC1106-P1 psma (I297V) Prame (L426(va),433(le)) MKC1106-P2 158va 433le 165V PSMA PRAME YES-1 YES-1 SSX2 H 42V SSX (A42V) MKC1106-P4 SSX2

15 A Multivalent Immunotherapeutic Candidate for varian Carcinoma PSMA YES % Cytotoxicity LCap 100:1 30:1 10:1 3:1 % C ytotoxicity Control L158vaC165V E:T 10 E:T 30 E:T 100 Target cells YES Target cells Peptide boost PRAME SSX2 % Cytotoxicity IF treated Target cells IF treated E:T 10 E:T 30 E:T 100 % Cytotoxicity T2 T2+SSX Target cells E:T 10 E:T 30 E:T MannKind Corporation. All rights reserved. o copying or distribution of

16 Directions Preclinical development Proof of principle in exploratory trials Safety, immunity, relationship with clinical outcome ptimization Composition Combinatorial approach Approved therapeutics ovel therapeutic candidates Efficacy trials 2005 MannKind Corporation. All rights reserved. o copying or distribution of

17 Acknowledgements Kent Smith Brenna Meisenburg Robb Pagarigan Christiana Sanders Victor Tam Xiping Liu Jian Gong Lisa Do Sean Hong Ludmila Krymskaya Liping Liu Amy Bauland Diljeet Joea Kris Krishnan Alfred Mann Hakan Edstrom Zhiyong Qiu Ani-Der Sarkissian Gene Girgis Sayuri Yatsubo Hong Tan Chih-Sheng Chiang Zheng Liu athalie Kertesz Anna Soloniona Sutao Zhu Liz Lantzy Thomas Kűndig, U. Zurich Rolf Zinkernagel, U. Zurich Jeffrey Weber, USC John Smith, Providence Portland Medical Center Evan Hersh, Arizona Cancer Center Adam Lerner, Boston Medical Center 2005 MannKind Corporation. All rights reserved. o copying or distribution of